Received Oct 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | Y1D49P1 | OT |
They have an expectant patient (pregnant) who got the IPOL in error and it was given intradermally with just 0.1 mL with no reported adverse event; They have an expectant patient (pregnant) who got the IPOL in error and it was given intradermally with just 0.1 mL with no reported adverse event; Initial information received on 15-Oct-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves an unknown age female patient who was exposed to vaccine IPV (VERO) [IPOL] in context of they have an expectant patient (pregnant) who got the ipol in error and it was given intradermally with just 0.1 ml with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported event occurred at unknown gestation period. The date of last menstrual period was not reported. The estimated due date was not reported. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 15-Oct-2025, they have an expectant patient (pregnant) who got the ipol 0.1 ml dose of suspect IPV (VERO) Suspension for injection of lot Y1D49P1 and expiry date: sep-2027 Frequency = once, Strength = standard via intradermal route in unknown administration site for Immunization in error and with no reported adverse event (exposure during pregnancy) (incorrect route of product administration) (latency: on same day). It was reported,She shared that the patient previously had 4 IPV doses as a younger adult and this vaccine was not the medication that was ordered for the patient.baby was delivered: No Action taken was not applicable. Additionally, at time of reporting, the outcome of the pregnancy is unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.